DANIEL R. PASSERI - 31 Mar 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
31 Mar 2022
Net transactions value
-$156,755
Form type
4
Filing time
04 Apr 2022, 17:29:48 UTC
Previous filing
29 Mar 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise +75,000 +76% 173,700 31 Mar 2022 Direct F1
transaction CUE Common Stock Tax liability $156,755 -32,122 -18% $4.88 141,578 31 Mar 2022 Direct
transaction CUE Common Stock Gift $0 -10,000 -7.1% $0.000000 131,578 31 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Restricted Stock Units Options Exercise $0 -75,000 -100% $0.000000* 0 31 Mar 2022 Common Stock 75,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3 One half of the Restricted Stock Units vested on September 30, 2021 and the balance vested on March 31, 2022.